Bio-Techne Corp (TECH)

Operating return on assets (Operating ROA)

		Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019
Operating income (ttm)	US$ in thousands	206,687	255,389	268,602	298,489	298,944	284,992	295,228	289,685	296,590	284,599	262,778	251,425	237,295	208,023	187,188	173,185	157,420	161,374	157,673	154,284
Total assets	US$ in thousands	2,703,870	2,721,170	2,730,750	2,755,360	2,638,690	2,599,700	2,363,400	2,350,720	2,294,800	2,299,890	2,304,850	2,270,190	2,262,960	2,084,640	2,067,870	2,053,100	2,027,590	1,999,020	1,998,420	1,925,030
Operating ROA		7.64%	9.39%	9.84%	10.83%	11.33%	10.96%	12.49%	12.32%	12.92%	12.37%	11.40%	11.08%	10.49%	9.98%	9.05%	8.44%	7.76%	8.07%	7.89%	8.01%

June 30, 2024 calculation

Operating ROA = Operating income (ttm) ÷ Total assets
= $206,687K ÷ $2,703,870K
= 7.64%

The operating return on assets (operating ROA) for Bio-Techne Corp has shown some fluctuations over the past few quarters. The trend indicates that the company's ability to generate operating income from its assets has varied.

In the most recent quarter, Jun 30, 2024, the operating ROA was 7.64%, which represents a decrease from the previous quarter's figure of 9.39%. This decline in operating ROA may suggest a decrease in the company's operational efficiency in utilizing its assets to generate earnings.

Looking back over the last few quarters, the company experienced a peak in operating ROA of 12.92% on Dec 31, 2022, followed by a subsequent decrease in the following quarter. Overall, the operating ROA has been fluctuating within a range of approximately 7.64% to 12.92%.

To gain a deeper understanding of the factors contributing to these fluctuations in operating ROA, further analysis of the company's financial performance, asset utilization, and profitability margins would be necessary. It would be important for stakeholders to closely monitor these trends to assess Bio-Techne Corp's operational efficiency and financial health.